A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts

Throughout the last three months, 4 analysts have evaluated NeuroPace NPCE, offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.75, with a high estimate of $22.00 and a low estimate of $9.00. Observing a 52.53% increase, the current average has risen from the previous average price target of $9.67.

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of how financial experts perceive NeuroPace is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeuroPace. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeuroPace compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of NeuroPace's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NeuroPace's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on NeuroPace analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind NeuroPace

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Breaking Down NeuroPace's Financial Performance

Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.

Revenue Growth: NeuroPace displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 47.23%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: NeuroPace's net margin is impressive, surpassing industry averages. With a net margin of -44.18%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): NeuroPace's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -38.61%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.2%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: NeuroPace's debt-to-equity ratio stands notably higher than the industry average, reaching 4.38. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Analyst Ratings: What Are They?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.